Genomic copy number alterations associated with the early brain metastasis of non-small cell lung cancer

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2013-2020

  Lee, Hye Won ^a,b   Seol, Ho Jun ^a   Choi, Yoon La ^a   Ju, Hyun Jung ^a   Joo, Kyeung Min ^a,c   Ko, Young Hyeh ^a   Lee, Jung Il ^a   Nam, Do Hyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Brain metastasis; Chromosomal aberration; Molecular inversion probe technology; Non small cell lung cancer; Prognostic marker

Indexed keywords

FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CHROMOSOME 11P; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME 3Q; CHROMOSOME 5P; CHROMOSOME 5Q; CHROMOSOME 6P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE DOSAGE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 84869777877     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1663     Document Type: Article

References (59)

1. Choi YW, Choi JS, Zheng LT, et al: Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer 55: 43-51, 2007. (Pubitemid 46038877)
2. Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC (eds): World Health Organization Classification of Tumors. Pathology and Genetics of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
3. Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392, 2004. (Pubitemid 38101633)
4. Salgia R, Hensing T, Campbell N, et al: Personalized treatment of lung cancer. Semin Oncol 38: 274-283, 2011.
5. Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (Suppl 8): S4-S66, 2001.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
7. Moran C: Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol 178: 1940-1948, 2011.
8. Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet 355: 479-485, 2000. (Pubitemid 30085163)
9. Hess KR, Varadhachary GR, Taylor SH, et al: Metastatic patterns in adenocarcinoma. Cancer 106: 1624-1633, 2006.
10. Feld R, Rubinstein LV and Weisenberger TH: Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 2: 1352-1358, 1984. (Pubitemid 15179536)
11. Bernards R and Weinberg RA: A progression puzzle. Nature 418: 823, 2002. (Pubitemid 34966286)
12. Wang Y, Moorhead M, Karlin-Neumann G, et al: Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res 33: e183, 2005.
13. Johnson CE, Gorringe KL, Thompson ER, et al: Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma. Breast Cancer Res Treat 133: 889-898, 2011.
14. Schiffman JD, Wang Y, McPherson LA, et al: Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. Cancer Genet Cytogenet 193: 9-18, 2009.
15. Wang Y, Moorhead M, Karlin-Neumann G, et al: Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol 8: R246, 2007.
16. Travis WD and Rekhtman N: Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 32: 22-31, 2011.
17. Travis WD, Rekhtman N, Riley GJ, et al: Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 5: 411-414, 2010.
18. Kang JU, Koo SH, Kwon KC, Park JW and Kim JM: Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 9: 237, 2009.
19. Yokoi S, Yasui K, Iizasa T, Imoto I, Fujisawa T and Inazawa J: TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res 9: 4705-4713, 2003. (Pubitemid 37323272)
20. Ubagai T, Matsuura S, Tauchi H, Itou K and Komatsu K: Comparative genomic hybridization analysis suggests a gain of chromosome 7p associated with lymph node metastasis in non-small cell lung cancer. Oncol Rep 8: 83-88, 2001.
21. Kang JU KS, Kwon KC, Park JW, Shin SY, Kim JM and Jung SS: High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescence in situ hybridization. J Korean Med Sci 22: 47-51, 2007.
22. Dehan E, Ben-Dor A, Liao W, et al: Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 56: 175-184, 2007. (Pubitemid 46613918)
23. Chujo M, Noguchi T, Miura T, Arinaga M, Uchida Y and Tagawa Y: Comparative genomic hybridization analysis detected frequent overrepresentation of chromosome 3q in squamous cell carcinoma of the lung. Lung Cancer 38: 23-29, 2002. (Pubitemid 35303356)
24. Kang JU, Koo SH, Kwon KC, Park JW and Jung SS: Gain of the EGFR gene located on 7p12 is a frequent and early event in squamous cell carcinoma of the lung. Cancer Genet Cytogenet 184: 31-37, 2008. (Pubitemid 351814968)
25. Massion PP, Kuo WL, Stokoe D, et al: Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62: 3636-3640, 2002. (Pubitemid 34728838)
26. Kikuchi T, Daigo Y, Ishikawa N, et al: Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 28: 799-805, 2006.
27. Robnett TJ, Machtay M, Stevenson JP, Algazy KM and Hahn SM: Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 19: 1344-1349, 2001. (Pubitemid 32202539)
28. Grinberg-Rashi H, Ofek E, Perelman M, et al: The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 15: 1755-1761, 2009.
29. Oh Y, Taylor S, Bekele BN, et al: Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer 115: 2930-2938, 2009.
30. Tam IY, Chung LP, Suen WS, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653, 2006.
31. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
32. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253, 2009.
33. Scagliotti G, Brodowicz T, Shepherd FA, et al: Treatment-byhistology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6: 64-70, 2011.
34. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J and Goldstraw P: The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4: 792-801, 2009.
35. Pisters KM, Evans WK, Azzoli CG, et al: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. J Clin Oncol 25: 5506-5518, 2007. (Pubitemid 350232227)
36. Bass AJ, Watanabe H, Mermel CH, et al: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242, 2009.
37. Rullinkov G, Tamme R, Sarapuu A, et al: Neuralized-2: expression in human and rodents and interaction with Delta-like ligands. Biochem Biophys Res Commun 389: 420-425, 2009.
38. Song R, Koo BK, Yoon KJ, et al: Neuralized-2 regulates a Notch ligand in cooperation with Mind bomb-1. J Biol Chem 281: 36391-36400, 2006. (Pubitemid 46041373)
39. Collins BJ, Kleeberger W and Ball DW: Notch in lung development and lung cancer. Semin Cancer Biol 14: 357-364, 2004. (Pubitemid 38993637)
40. Westhoff B, Colaluca IN, D'Ario G, et al: Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA 106: 22293-22298, 2009.
41. Yang Y, Ahn YH, Gibbons DL, et al: The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR- 200-dependent pathway in mice. J Clin Invest 121: 1373-1385, 2011.
42. Peter ME, Budd RC, Desbarats J, et al: The CD95 receptor: apoptosis revisited. Cell 129: 447-450, 2007. (Pubitemid 46660984)
43. Peter ME, Legembre P and Barnhart BC: Does CD95 have tumor promoting activities? Biochim Biophys Acta 1755: 25-36, 2005. (Pubitemid 40720239)
44. Mitsiades CS, Poulaki V, Fanourakis G, et al: Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 12: 3705-3712, 2006. (Pubitemid 44000250)
45. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G and Peter ME: CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 23: 3175-3185, 2004. (Pubitemid 39093611)
46. Chen L, Park SM, Tumanov AV, et al: CD95 promotes tumour growth. Nature 465: 492-496, 2010.
47. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X and Cao X: Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 182: 3801-3808, 2009.
48. Kleber S, Sancho-Martinez I, Wiestler B, et al: Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13: 235-248, 2008. (Pubitemid 351324880)
49. Masszi A, Speight P, Charbonney E, et al: Fate-determining mechanisms in epithelial-myofibroblast transition: major inhibitory role for Smad3. J Cell Biol 188: 383-399, 2010.
50. Wang J, Zohar R and McCulloch CA: Multiple roles of alphasmooth muscle actin in mechanotransduction. Exp Cell Res 312: 205-214, 2006. (Pubitemid 41814831)
51. Han M, Liu M, Wang Y, et al: Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem 363: 427-436, 2012.
52. Owens GK and Thompson MM: Developmental changes in isoactin expression in rat aortic smooth muscle cells in vivo. Relationship between growth and cytodifferentiation. J Biol Chem 261: 13373-13380, 1986. (Pubitemid 17006921)
53. Pirozzi G, Tirino V, Camerlingo R, et al: Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non-small cell lung cancer cell line. PLoS One 6: e21548, 2011.
54. Valcz G, Sipos F, Krenacs T, et al: Increase of alpha-SMA(+) and CK (+) cells as an early sign of epithelial-mesenchymal transition during colorectal carcinogenesis. Pathol Oncol Res 18: 371-376, 2012.
55. Perez OD, Kinoshita S, Hitoshi Y, et al: Activation of the PKB/AKT pathway by ICAM-2. Immunity 16: 51-65, 2002. (Pubitemid 34143216)
56. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
57. Ji H, Kumm J, Zhang M, et al: Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. Cancer Res 66: 7910-7919, 2006. (Pubitemid 44299153)
58. Lapuk A, Volik S, Vincent R, et al: Computational BAC clone contig assembly for comprehensive genome analysis. Genes Chromosomes Cancer 40: 66-71, 2004. (Pubitemid 38524622)
59. Wang Y, Carlton VE, Karlin-Neumann G, et al: High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2: 8, 2009.